Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV)

Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, Baudin E, Caplin ME Journal article Diagnosis and Therapy before Assisted Reproductive TreatmentsGuideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019)-Part 1, Basic Assessment of the Woman (2019) Toth B, Baston-Buest DM, Behre HM, Bielfeld A, Bohlmann M, Buehling K, Dittrich R, et al. Journal article Diagnosis and Treatment Before Assisted Reproductive Treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) – Part 2, Hemostaseology, Andrology, Genetics and History of Malignant Disease (2019) Toth B, Baston-Buest DM, Behre H, Bielfeld A, Bohlmann M, Buehling K, Dittrich R, et al. Journal article Estimating the effect size of the 15Q11.2 BP1-BP2 deletion and its contribution to neurodevelopmental symptoms: recommendations for practice (2019) Jønch AE, Douard E, Moreau C, Van Dijck A, Passeggeri M, Kooy F, Puechberty J, et al. Journal article Problematic smartphone use in young Swiss men: Its association with problematic substance use and risk factors derived from the pathway model (2019) Dey M, Studer J, Schaub MP, Gmel G, Ebert D, Lee JYC, Haug S Journal article ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study (2019) Kolios AGA, Hueber A, Michetti P, Mrowietz U, Mustak-Blagusz M, Sator PG, Reinshagen M, et al. Journal article Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study (2019) Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al. Journal article, Review article Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study (2019) Lamarca A, Ronot M, Moall S, Crona J, Opalinska M, Lopez C, Pezzutti D, et al. Conference contribution Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study (2019) Pavel ME, Dromain C, Thanh TXM, Houchard A Conference contribution Electrical spinal cord stimulation must preserve proprioception to enable locomotion in humans with spinal cord injury (2018) Formento E, Minassian K, Wagner F, Mignardot JB, Le Goff-Mignardot CG, Rowald A, Bloch J, et al. Journal article